Patients with low ALT levels are at increased risk for severe COVID-19

被引:1
|
作者
Genzel, Dor [1 ]
Katz, Lior H. [1 ,2 ]
Safadi, Rifaat [1 ,3 ]
Rozenberg, Aliza [4 ]
Milgrom, Yael [1 ,3 ]
Jacobs, Jeremy M. [1 ,4 ]
Shafrir, Asher [1 ,2 ,5 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Gastroenterol, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Liver Inst, Fac Med, Hadassah Med Ctr, Jerusalem, Israel
[4] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Geriatr & Geriatr Rehabil, Jerusalem, Israel
[5] Meuhedet Hlth Maintenance Org, Tel Aviv, Israel
关键词
alanine transaminase; sarcopenia; COVID-19; mortality; frailty; FRAILTY; MORTALITY; ASSOCIATION; SURVIVAL;
D O I
10.3389/fmed.2023.1231440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Frailty is a known risk factor for many diseases, including COVID-19. However, many frail patients are undiagnosed as the diagnosis can be cumbersome. Alanine transaminase (ALT) is found not only in the liver but also in the muscle tissue, and multiple studies show that frail sarcopenic patients have lower ALT. Frail patients are at increased risk for severe COVID-19. We evaluated the association between pre-infection low ALT and the risk for severe COVID-19. Methods: We collected data regarding all subjects tested for SARS-CoV-2 between 1 March 2020 and 31 December 2021 from a national state-mandatory HMO in Israel, serving more than 1.3 million patients. Clinical and laboratory data were collected, including ALT from the year prior to infection. Severe COVID-19 was defined either as death, ICU admission, or >= 10 hospitalization days. Patients with low ALT (ALT <= 10 IU/l) were compared with patients with normal ALT (11-40 IU/l). Patients younger than 18 years with a diagnosis of liver disease and with ALT > 40 IU/l were excluded. Results: During the study period, 58,961 patients tested positive for SARS-CoV-2. The patients in the low ALT group were younger (40.53 vs. 42.73, p < 0.001), less likely to be males (12.3 vs. 38.7%, p < 0.001), and had lower BMI (25.97 vs. 27.15, p < 0.001). The patients in the low ALT group had higher mortality (2.36 vs. 0.57%, p < 0.001), more ICU hospitalizations (0.49 vs. 0.41%, p = 0.47), and more prolonged hospitalizations [2.63% (95% CI 2-3.2%) vs. 0.98% (95% CI 0.86-1.1%) p < 0.001]. In multivariate logistic regression analyses, low ALT was associated with an increased risk of severe COVID-19, with increased mortality (OR 1.88, 95% CI 1.37-2.56) and prolonged hospitalization (OR 1.78, 95% CI 1.33-2.35). Conclusion: Low ALT level prior to infection is a significant risk factor for morbidity and mortality from COVID-19 infection. Further studies are warranted to address treatment options for this population.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Are CLD Patients at increased Risk for severe COVID-19 Progression?
    Metzger, Leandra
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1258 - +
  • [2] Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19
    Fromonot, Julien
    Gette, Mickael
    Ben Lassoued, Amin
    Gueant, Jean-Louis
    Gueant-Rodriguez, Rosa-Maria
    Guieu, Regis
    [J]. CLINICAL NUTRITION, 2022, 41 (12) : 3115 - 3119
  • [3] COVID-19: Risk factors for increased mortality in younger COVID-19 patients
    不详
    [J]. ERNAHRUNGS UMSCHAU, 2022, 69 (06): : M297 - M297
  • [4] No increased risk of severe COVID-19 in asthma treated with biologics
    Beyaz, Sengul
    Erecan, Emircan
    Mutlu, Pinar
    Ozseker, Zeynep Ferhan
    [J]. EURASIAN JOURNAL OF PULMONOLOGY, 2022, 24 (02) : 85 - 94
  • [5] COVID-19 during pregnancy: increased risk of severe illness
    不详
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2022, 217 (05) : 223 - 223
  • [6] Are women with asthma at increased risk for severe COVID-19? Comment
    Fernando, Mario
    Agusti, Alvar
    Dharmage, Shyamali
    Lodge, Caroline
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (02): : 125 - 126
  • [7] Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores
    Yao, Renling
    Zhu, Li
    Wang, Jian
    Liu, Jiacheng
    Xue, Ruifei
    Xue, Leyang
    Liu, Longgen
    Li, Chunyang
    Zhao, Haiyan
    Cheng, Juan
    Huang, Songping
    Li, Yang
    Zhao, Xiang-an
    Zhu, Chuanwu
    Li, Ming
    Huang, Rui
    Wu, Chao
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (08)
  • [8] Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
    Schulze-Koops, Hendrik
    Krueger, Klaus
    Vallbracht, Inka
    Hasseli, Rebecca
    Skapenko, Alla
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05)
  • [9] Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes
    Marcinkiewicz, Janusz
    Mazurek, Henryk
    Majka, Grzegorz
    Chain, Benjamin
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2020, 130 (10): : 919 - 920
  • [10] Low vitamin D levels and increased neutrophil in patients admitted at ICU with COVID-19
    Pimentel, Gustavo D.
    Dela Vega, Maria C. M.
    Pichard, Claude
    [J]. CLINICAL NUTRITION ESPEN, 2021, 44 : 466 - 468